Evaxion Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Loss: $3.7 million for Q2 2026, in line with expectations.

Cash Position: $14 million at the end of Q2, with a confirmed cash runway extending into the second half of 2027.

Operating Expenses: Slightly reduced overall, with a notable decrease in general and administrative costs, while R&D expenses increased slightly due to ongoing program developments.

2Strategic Updates and Business Highlights

R&D Pipeline: Focused on four core platforms, with significant progress in:

EVX-01: Personalized neoantigen cancer vaccine for advanced melanoma, with upcoming 3-year Phase 2 data to be presented at ESMO.

EVX-05: New off-the-shelf vaccine for glioblastoma, leveraging AI-Immunology to target conserved antigens.

EVX-04: Off-the-shelf vaccine for AML, progressing towards regulatory filing.

EVX-V1: CMV vaccine program showing promising preclinical data.

AI-Immunology Recognition: The platform received recognition through the Galien UK Award, validating its potential across various disease areas.

3Forward Guidance and Outlook

Upcoming Milestones:

Presentation of EVX-01 3-year data at ESMO in October.

Regulatory filing for EVX-04 expected by the end of 2026.

Continued development of EVX-05 with IND-enabling activities underway, though specific timelines are not yet established.

Business Development: Ongoing discussions with potential partners, bolstered by recent positive data from similar industry programs.

4Bad News, Challenges, or Points of Concern

Partnership Discussions: While there is interest in partnerships, the CEO indicated that discussions have been cautious, with some delays due to the need for clinical validation in the field.

Cash Burn Rate: The current burn rate of approximately $4 million per quarter raises questions about future funding needs, although management is confident in their cash runway and potential for partnerships or ATM facility utilization.

Market Competition: The success of competitors like Moderna and Merck in personalized vaccines could increase competitive pressures.

5Notable Q&A Insights

EVX-05 Development: The collaboration with Duke University is critical for target discovery and patient data analysis, with ongoing work to finalize lead candidates.

EVX-01 Durability Expectations: Clinically meaningful results for EVX-01 are expected to show durable responses, which would enhance partnership discussions.

Broader Application of ERV Approach: The potential for the ERV-targeting approach to be applicable across various solid tumors was highlighted, indicating a strategic expansion opportunity for Evaxion's oncology franchise.

Cash Management Strategy: Management is exploring various avenues for cash infusion, including potential partnerships and utilizing their ATM facility. This summary encapsulates the key financial metrics, strategic updates, forward guidance, challenges, and insights from the Q&A, providing a comprehensive overview of Evaxion's current position and outlook.